Sekine T, Perez Potti A, Rivera Ballesteros O, Stralin K, Gorin J, Olsson A, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158-168.e14 pubmed publisher

Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24:724-730 pubmed publisher

Sahin U, Derhovanessian E, Miller M, Kloke B, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222-226 pubmed publisher

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217-221 pubmed publisher

Kranz L, Diken M, Haas H, Kreiter S, Loquai C, Reuter K, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016;534:396-401 pubmed publisher

Gubin M, Zhang X, Schuster H, Caron E, Ward J, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577-81 pubmed publisher

Weiland O, Ahlen G, Diepolder H, Jung M, Levander S, Fons M, et al. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther. 2013;21:1796-805 pubmed publisher

Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther. 2011;19:1737-46 pubmed publisher

Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874-84 pubmed publisher

Lunemann J, Jelcic I, Roberts S, Lutterotti A, Tackenberg B, Martin R, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med. 2008;205:1763-73 pubmed publisher

Currier J, Kuta E, Turk E, Earhart L, Loomis Price L, Janetzki S, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods. 2002;260:157-72 pubmed

Czerkinsky C, Andersson G, Ekre H, Nilsson L, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods. 1988;110:29-36 pubmed